Gainers

• Bluejay Diagnostics (NASDAQ:BJDX) shares moved upwards by 43.0% to $1.43 during Wednesday's pre-market session. The company's market cap stands at $1.0 million.
• Estrella Immunopharma (NASDAQ:ESLA) stock rose 22.14% to $0.86. The market value of their outstanding shares is at $30.2 million.
• Curanex Pharmaceuticals (NASDAQ:CURX) stock moved upwards by 15.38% to $0.24. The market value of their outstanding shares is at $5.9 million.
• Travere Therapeutics (NASDAQ:TVTX) shares moved upwards by 13.34% to $63.49. The market value of their outstanding shares is at $5.2 billion. The company's, Q2 earnings came out yesterday.
• Sight Sciences (NASDAQ:SGHT) shares increased by 11.52% to $6.29. The company's market cap stands at $306.8 million. As per the news, the Q2 earnings report came out today.
• Orthofix Medical (NASDAQ:OFIX) stock moved upwards by 11.06% to $13.55. The company's market cap stands at $493.1 million. As per the press release, Q2 earnings came out today.

Losers

• Autonomix Medical (NASDAQ:AMIX) stock fell 34.0% to $12.88 during Wednesday's pre-market session. The market value of their outstanding shares is at $10.5 million.
• Vivos Therapeutics (NASDAQ:VVOS) shares declined by 30.77% to $0.32. The company's market cap stands at $6.4 million.
• Jupiter Neurosciences (NASDAQ:JUNS) stock decreased by 29.83% to $0.07. The market value of their outstanding shares is at $5.8 million.
• VSee Health (NASDAQ:VSEE) stock decreased by 29.53% to $0.06. The company's market cap stands at $4.6 million.
• China SXT Pharmaceuticals (NASDAQ:SXTC) shares decreased by 28.27% to $0.09. The company's market cap stands at $4.7 million.
• Adagio Medical Holdings (NASDAQ:ADGM) shares fell 18.62% to $0.65. The company's market cap stands at $17.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.